



Tranilast, an analogue of tryptophan catabolites, induces allograft tolerance by CD161+ cells

Séverine Ménoret, Séverine Bézie, Xian-Liang Li, Claire Usal, Lise Caron,
Ignacio Anegón

► To cite this version:

Séverine Ménoret, Séverine Bézie, Xian-Liang Li, Claire Usal, Lise Caron, et al.. Tranilast, an analogue of tryptophan catabolites, induces allograft tolerance by CD161+ cells. 6th european workshop on immune-mediated inflammatory diseases, Nice, France. pp.P27. inserm-00643970

HAL Id: inserm-00643970

<https://www.hal.inserm.fr/inserm-00643970>

Submitted on 23 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

Tranilast, an analogue of tryptophan catabolites, induces allograft tolerance by CD161⁺ cells

Séverine Ménoret^{1*}, Séverine Bézie², Xian-Liang Li², Claire Usal², Lise Caron², Ignacio Anegón²

From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011

Background

Indoleamine 2, 3-dioxygenase (IDO) converts tryptophan in various catabolites and has been shown to induce immune tolerance in different immune-mediated diseases, including organ transplantation. One of these tolerogenic metabolites is anthranilic acid. Tranilast is a clinically approved, structural and functional analogue of anthranilic acid that has been recently shown to be effective in murine models of multiple sclerosis and rheumatoid arthritis. We examined the effect of tranilast in a rat cardiac allograft model.

Materials and methods

Lewis 1W rat hearts were grafted in MHC-mismatched Lewis 1A rats. The receiver is orally treated with 650mg/kg of tranilast daily for 30 days. Total splenocytes and purified spleen cell subtypes sorted by FACS Aria were transferred to sublethally irradiated rats by *i.v* injection the day before transplantation.

Results

Graft survival in recipients treated with tranilast were significantly prolonged (66.3 ± 46.7 days, $n=53$, $p<0,0001$) when compared to control group (8.3 ± 2.3 days, $n=6$) and in 45% of recipients ($n=53$) tranilast induced tolerance (>100 days survival). Adoptive transfer of total splenocytes from tolerant tranilast-treated rats to naïve rats resulted in tolerance in all animals ($n=5$). Moreover, splenocytes from these adoptively transferred tolerant recipients were again capable of transferring tolerance to all naïve recipients ($n=5$). Tolerant splenocytes depleted of T and B cells ($n=6$) or depleted of T, B and DCs ($n=5$) transferred tolerance. Importantly, depletion of CD161⁺ cells from T, B and DCs-depleted splenocytes abrogated tolerance transfer (9.3 ± 0.6 $n=3$). To confirm these

results, we adoptively transferred CD161⁺TCR⁻ cells from tolerant rats which resulted in tolerance (130 ± 91.6 days, $n=5$, 3/5 recipients >100 days) whereas CD161⁻TCR⁻ cells from the same animals did not (12.7 ± 4.6 days, $n=3$, $p<0,005$).

Discussion

This is the first demonstration that tranilast mediates transplantation tolerance. Tolerance was active and transferable by CD161⁺TCR⁻ cells that comprise NK cells (CD161^{high}) and myeloid-derived suppressor cells (CD161^{low}). Experiments are under way to define which of these cell populations mediate tranilast-induced tolerance and by which downstream mechanisms.

Author details

¹Platform Transgenic Rats Nantes IBISA-CNRS, Nantes, France. ²INSERM UMR 643, Nantes, France.

Published: 23 November 2011

doi:10.1186/1479-5876-9-S2-P27

Cite this article as: Ménoret et al.: Tranilast, an analogue of tryptophan catabolites, induces allograft tolerance by CD161⁺ cells. *Journal of Translational Medicine* 2011 **9**(Suppl 2):P27.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Platform Transgenic Rats Nantes IBISA-CNRS, Nantes, France
Full list of author information is available at the end of the article